Biotech Values

[walldiver]

GTOP and FVRL are trialing competing immunotherapy products, both in Phase III, for the same indication (NHL after Rituxan primary therapy), although FVRL's trial protocol might be different. I can't recall if there is more of a concurrent Rituxan component to the FVRL Phase III. Anyway, the setbacks you recall are related to the trials continuing after DSMB reviewed the interim data, with accompanying drops in the stock prices.